INDIANAPOLIS, Ind. (ADAMS) – Drugmaker Eli Lilly reports its Alzheimer’s treatment donanemab significantly slowed the progression of the disease in clinical trials.
Lilly released trial data on the company’s website on Wednesday. It showed that patients who received the monthly antibody infusion during an 18-month study showed a 35-percent lower decline in memory, thinking, and their ability to perform daily activities.
The company said Lilly plans to apply for FDA approval of the drug as soon as this quarter.
Read more here
